CANTARGIA Aktie

>CANTARGIA Performance

1 Woche: -1,0%

1 Monat: -14,6%

3 Monate: -2,8%

6 Monate: +59,6%

1 Jahr: +259,9%

laufendes Jahr: -2,8%

>CANTARGIA Aktie

Name:

CANTARGIA AB

Land:

Schweden

Sektor:

Gesundheit

ISIN/ Wkn:

SE0006371126 / A2JAZX

Symbol/ Ticker:

7V3 (Frankfurt)

Kürzel:

FRA:7V3, ETR:7V3, 7V3:GR

Index:

Webseite:

https://cantargia.com/

Profil:

Cantargia AB (publ) is a Sweden-based biotechnology company specializing in the development of antibody therapeutics for cancer treatment. Its primary focus is on targeting the Interleukin-1 receptor accessory protein (IL1RAP), a cell-surface recepto..
>Volltext..

Marktkapitalisierung:

95.48 Mio. EUR

Unternehmenswert:

69.53 Mio. EUR

Umsatz:

29.69 Mio. EUR

EBITDA:

14.78 Mio. EUR

Nettogewinn:

13.78 Mio. EUR

Gewinn je Aktie:

0.06 EUR

Schulden:

Liquide Mittel:

26.42 Mio. EUR

Operativer Cashflow:

14.07 Mio. EUR

Bargeldquote:

9.41

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CANTARGIA

Letzte Datenerhebung:

05.04.26

>CANTARGIA Kennzahlen

Aktien/ Unternehmen:

Aktien: 248.61 Mio. St.

Frei handelbar: 95.26%

Leerverk. Aktien: -

Rückkaufquote: -10.49%

Mitarbeiter: 22

Umsatz/Mitarb.: 1.35 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 111.28%

Bewertung:

KGV: 7.45

KGV lG: -

KUV: 3.21

KBV: 4.12

PEG-Ratio: -

EV/EBITDA: 4.7

Rentabilität:

Bruttomarge: -

Gewinnmarge: 46.41%

Operative Marge: 48.75%

Managementeffizenz:

Gesamtkaprendite: 62.93%

Eigenkaprendite: 76.91%

>CANTARGIA Peer Group

Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung

>CANTARGIA Chart & Kurs - Stuttgart

>CANTARGIA News

05.03.26 - 10:31	Cantargia to Participate at Van Lanschot Kempen′s Life Sciences Conference (Accesswire)
	LUND, SE / ACCESS Newswire / March 5, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings......

23.02.26 - 09:30	Cantargia to Participate in TD Cowen′s Annual Healthcare Conference (Accesswire)
	LUND, SE / ACCESS Newswire / February 23, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargia's management will participate in and host 1-1 meet......

20.02.26 - 07:30	Cantargia Publishes Full Year Report 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / February 20, 2026 / Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) full year report for 2025 is now available on the company's web page www.can......

06.02.26 - 11:30	Invitation to the Presentation of Cantargia′s Annual Results for 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CE......

28.01.26 - 10:30	Cantargia to Participate at Leerink Partners Global Healthcare Conference (Accesswire)
	LUND, SE / ACCESS Newswire / January 28, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargias management will participate in one-o......

23.01.26 - 08:06	Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study (Accesswire)
	LUND, SE / ACCESS Newswire / January 23, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 1b/2 clinical trial investigating nadunolimab in comb......

05.12.25 - 08:06	Cantargia Provides Update on Overall Survival Data from TRIFOUR (Accesswire)
	LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study......

19.11.25 - 16:06	Earnings Call Transkript: Cantargia meldet im 3. Quartal 2025 erstmals Umsatzerlöse/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

19.11.25 - 07:30	Cantargia Publishes Interim Report for January to September 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on ......

12.11.25 - 09:07	Cantargia Presents Nomination Committee Ahead of 2026 AGM (Accesswire)
	LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appoint......

05.11.25 - 09:54	Invitation to the Presentation of Cantargia′s Interim Report January-September 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on W......

23.10.25 - 13:54	Cantargia to Participate in Upcoming Conferences (Accesswire)
	LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel......

02.10.25 - 08:06	Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer (Accesswire)
	LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical......

01.10.25 - 00:30	Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC (Accesswire)
	LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while thi......

11.09.25 - 08:06	Cantargia Closes the Acquisition of CAN10 by Otsuka (Accesswire)
	LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Ot......

27.08.25 - 08:06	Cantargia Granted Important US Patent for Nadunolimab (Accesswire)
	LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the pa......

21.08.25 - 07:30	Cantargia Publishes Half-Year Report 2025 (Accesswire)
	LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO ......

18.08.25 - 18:54	Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer (Accesswire)
	Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and bu......

12.08.25 - 10:42	Invitation to the Presentation of Cantargia′s H1 2025 Report (Accesswire)
	LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August......

17.07.25 - 21:54	Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer (Accesswire)
	LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolera......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram